Alessandro Fichera1, Marco E Allaix. 1. Department of Surgery, University of Washington Medical Center, 1959 NE Pacific St, Box 356410, Seattle, WA, 98195, USA, afichera@uw.edu.
Abstract
BACKGROUND: Treatment of rectal cancer has dramatically evolved during the last three decades shifting toward a tailored approach based on preoperative staging and response to neoadjuvant combined modality therapy (CMT). METHODS: A literature search was performed using PubMed/Medline electronic databases. RESULTS: Selected patients with T1 N0 rectal cancer are best treated with local excision by transanal endoscopic microsurgery (TEM). Satisfactory results have been reported after CMT and TEM for the treatment of highly selected T2 N0 rectal cancers. CMT followed by rectal resection and total mesorectal excision is considered the standard of care for the treatment of locally advanced rectal cancer. However, a subset of stage II and III patients may not require neoadjuvant radiation treatment. Finally, there are mounting data supporting a "watch and wait" approach or local excision in patients with complete clinical response after neoadjuvant CMT. CONCLUSIONS: Current evidence shows that selected T1 N0 rectal cancers can be managed by TEM alone, while locally advanced cancers should be treated by CMT followed by radical surgery. Studies are underway to identify patients that do not benefit from neoadjuvant radiation therapy. A non-operative approach in case of complete clinical response must be validated by large prospective studies.
BACKGROUND: Treatment of rectal cancer has dramatically evolved during the last three decades shifting toward a tailored approach based on preoperative staging and response to neoadjuvant combined modality therapy (CMT). METHODS: A literature search was performed using PubMed/Medline electronic databases. RESULTS: Selected patients with T1 N0 rectal cancer are best treated with local excision by transanal endoscopic microsurgery (TEM). Satisfactory results have been reported after CMT and TEM for the treatment of highly selected T2 N0 rectal cancers. CMT followed by rectal resection and total mesorectal excision is considered the standard of care for the treatment of locally advanced rectal cancer. However, a subset of stage II and III patients may not require neoadjuvant radiation treatment. Finally, there are mounting data supporting a "watch and wait" approach or local excision in patients with complete clinical response after neoadjuvant CMT. CONCLUSIONS: Current evidence shows that selected T1 N0 rectal cancers can be managed by TEM alone, while locally advanced cancers should be treated by CMT followed by radical surgery. Studies are underway to identify patients that do not benefit from neoadjuvant radiation therapy. A non-operative approach in case of complete clinical response must be validated by large prospective studies.
Authors: Salvatore Pucciarelli; Carlo Capirci; Urso Emanuele; Paola Toppan; Maria Luisa Friso; Gian Maria Pennelli; Giovanni Crepaldi; Lara Pasetto; Donato Nitti; Mario Lise Journal: Ann Surg Oncol Date: 2005-02-04 Impact factor: 5.344
Authors: Dieter Hahnloser; Bruce G Wolff; David W Larson; Jennifer Ping; Santhat Nivatvongs Journal: Dis Colon Rectum Date: 2005-03 Impact factor: 4.585
Authors: D A M Sloothaak; D E Geijsen; N J van Leersum; C J A Punt; C J Buskens; W A Bemelman; P J Tanis Journal: Br J Surg Date: 2013-03-27 Impact factor: 6.939
Authors: Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: G Lezoche; M Baldarelli; Mario Guerrieri; A M Paganini; A De Sanctis; S Bartolacci; E Lezoche Journal: Surg Endosc Date: 2007-10-18 Impact factor: 4.584
Authors: M L Malmstrøm; S Brisling; T W Klausen; A Săftoiu; T Perner; P Vilmann; I Gögenur Journal: Int J Colorectal Dis Date: 2017-11-07 Impact factor: 2.571
Authors: Patrick E Young; Craig M Womeldorph; Eric K Johnson; Justin A Maykel; Bjorn Brucher; Alex Stojadinovic; Itzhak Avital; Aviram Nissan; Scott R Steele Journal: J Cancer Date: 2014-03-15 Impact factor: 4.207